Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective

Walia, Harleen Kaur; Sharma, Parul; Singh, Navneet; Sharma, Siddharth

doi:10.1007/s11864-022-00949-1

Cited by 14 publications

(6 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, the immune check-point inhibitors (ICIs) have been widely used for therapy in lung cancers [ 40 ], and the therapeutic effect is related to the expressions of immune check-points in tumors and TMB [ 41 ]. In this study, we found that LUAD patients with higher riskscore had higher levels of TMB, including TTN, CSMD3, MUC16, RYR2, LRB1P and ZFHX4 mutations, which would produce more neoantigens and improve T-cell recognition [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of crucial anoikis-related genes as novel biomarkers and potential therapeutic targets for lung adenocarcinoma via bioinformatic analysis and experimental verification

Wu,

Zhang,

You

et al. 2024

Aging

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is a malignant tumor of the respiratory system that has a poor 5-year survival rate. Anoikis, a type of programmed cell death, contributes to tumor development and metastasis. The aim of this study was to develop an anoikis-based stratified model, and a multivariable-based nomogram for guiding clinical therapy for LUAD. Through differentially expressed analysis, univariate Cox, LASSO Cox regression, and random forest algorithm analysis, we established a 4 anoikis-related genes-based stratified model, and a multivariable-based nomogram, which could accurately predict the prognosis of LUAD patients in the TCGA and GEO databases, respectively. The low and high-risk score LUAD patients stratified by the model showed different tumor mutation burden, tumor microenvironment, gemcitabine sensitivity and immune checkpoint expressions. Through immunohistochemical analysis of clinical LUAD samples, we found that the 4 anoikisrelated genes (PLK1, SLC2A1, ANGPTL4, CDKN3) were highly expressed in the tumor samples from clinical LUAD patients, and knockdown of these genes in LUAD cells by transfection with small interfering RNAs significantly inhibited LUAD cell proliferation and migration, and promoted anoikis. In conclusion, we developed an anoikisbased stratified model and a multivariable-based nomogram of LUAD, which could predict the survival of LUAD patients and guide clinical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of crucial anoikis-related genes as novel biomarkers and potential therapeutic targets for lung adenocarcinoma via bioinformatic analysis and experimental verification

Wu,

Zhang,

You

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…In summary, the major function of the anti-CTLA-4 is to allow T-cell activation, proliferation, and migration to the tumor tissue mediating the death of tumor cells [ 8 , 28 , 35 , 36 ]. The anti-CTLA-4 mechanism of action is described in Figure 1 .…”

Section: Immunotherapymentioning

confidence: 99%

New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination

Fernandes

Oliveira

Sousa

et al. 2023

IJMS

View full text Add to dashboard Cite

Lung cancer is the second most common cancer in the world, being the first cause of cancer-related mortality. Surgery remains the only potentially curative treatment for Non-Small Cell Lung Cancer (NSCLC), but the recurrence risk remains high (30–55%) and Overall Survival (OS) is still lower than desirable (63% at 5 years), even with adjuvant treatment. Neoadjuvant treatment can be helpful and new therapies and pharmacologic associations are being studied. Immune Checkpoint Inhibitors (ICI) and PARP inhibitors (PARPi) are two pharmacological classes already in use to treat several cancers. Some pre-clinical studies have shown that its association can be synergic and this is being studied in different settings. Here, we review the PARPi and ICI strategies in cancer management and the information will be used to develop a clinical trial to evaluate the potential of PARPi association with ICI in early-stage neoadjuvant setting NSCLC.

show abstract

“… 10 Most importantly, immunotherapeutic concepts have been discussed as especially promising for future perspectives in SCLC. 14 Indeed, representing the most significant therapeutic novelties for decades, immunotherapeutic targeting of anti-programmed death-ligand 1 (PD-L1) has been recently included into the treatment guidelines for extensive-stage SCLC patients. 15 , 16 Moreover, immune-checkpoint-mediated blockage of CD47, a ‘don’t-eat-me’ cell-surface signal for macrophages, has been shown to effectively suppress SCLC tumor growth in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer

Lang¹,

Lantos²,

Egger³

et al. 2022

ESMO Open

View full text Add to dashboard Cite

Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective

Cited by 14 publications

References 116 publications

Identification of crucial anoikis-related genes as novel biomarkers and potential therapeutic targets for lung adenocarcinoma via bioinformatic analysis and experimental verification

Identification of crucial anoikis-related genes as novel biomarkers and potential therapeutic targets for lung adenocarcinoma via bioinformatic analysis and experimental verification

New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination

Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer

Contact Info

Product

Resources

About